News - Bright Peak Therapeutics

April, 2023

Bright Peak Presents New Data at AACR: BPT567 A First-in-Class Multifunctional αPD1-IL18 Immunocytokine

November, 2022

Bright Peak Presents New Therapeutics Highlighted by Multifunctional PD-1 Targeted Immunocytokines at SITC 2022

Bright Peak Therapeutics to Present Innovative Best-in-Class and Multifunctional Regulatory T Cell (Treg) Enhancers at the 10th International Conference on Autoimmunity: Mechanisms and Novel Treatments

October, 2022

Bright Peak Therapeutics Announces Formation of World Class Immuno-Oncology Scientific Advisory Board

August, 2022

Bright Peak Therapeutics Announces the Appointment of Cancer Immunotherapy Leader Jon Wigginton, M.D., as President of Research and Development

March, 2022

Bright Peak Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting

February, 2022

Bright Peak Therapeutics Appoints Leena Gandhi, M.D., Ph.D., to its Board of Directors

November, 2021

Bright Peak Therapeutics Appoints Jacob Chacko, M.D., as Chair of its Board of Directors

November, 2021

Bright Peak Therapeutics Licenses Rights to Livzon’s Anti-PD-1 Antibody LZM009 to Develop Novel PD-1 Targeted Immunocytokines

June, 2021

Bright Peak Therapeutics Announces $107 Million Series B Financing and Expanded Board of Directors

March, 2021

Bright Peak Therapeutics Inc. and Ajinomoto Co., Inc. Enter into a Research Collaboration and License Agreement to Create Novel Immunocytokines

April, 2020

Versant Ventures Launches Bright Peak Therapeutics